Role of natural killer cells for immunotherapy in chronic myeloid leukemia (Review)

Lee,Hye‑Rim; Baek,Kwang‑Hyun

doi:10.3892/or.2019.7059

Role of natural killer cells for immunotherapy in chronic myeloid leukemia (Review)

Authors:
- Hye‑Rim Lee
- Kwang‑Hyun Baek
View Affiliations

Affiliations: Department of Biomedical Science, CHA University, CHA General Hospital, Seongnam, Gyeonggi 13488, Republic of Korea
Published online on: March 13, 2019 https://doi.org/10.3892/or.2019.7059
Pages: 2625-2635

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The majority of natural killer (NK) cells serve an important role in eliminating malignant cells. The cytotoxic effects of NK cells were first identified against leukemia cells, and it is now hypothesized that they may have a critical role in leukemia therapy. The cellular functions of NK cells are mediated by their cell surface receptors, which recognize ligands on cancer cells. The role of NK cells is specifically regulated by the activating or inhibitory killer cell immunoglobulin‑like receptors (KIRs) on their surface, which bind to the human leukocyte antigen (HLA) class I ligands present on the target cells. The association between KIR and HLA is derived from the diversity of KIR/HLA gene profiles present in different individuals, and this determines the cytotoxic effect of NK cells on cancer cells. Chronic myeloid leukemia (CML) is a hematological leukemia characterized by the hyper‑proliferation of myeloid cells, with the majority of patients with CML presenting with abnormal immune cells. Tyrosine kinase inhibitors are the present standard therapy for CML, but are associated with numerous adverse side effects. Various studies have proposed CML therapy by immunotherapeutic approaches targeting the immune cells. This review summarizes the contents of NK cells and the association between KIR/HLA and leukemia, especially CML. This is followed by a discussion on the development of NK cell immunotherapy in hematological malignancies and research into strategies to enhance NK cell function for CML treatment.

View Figures

View References

1	Handgretinger R, Lang P and André MC: Exploitation of natural killer cells for the treatment of acute leukemia. Blood. 127:3341–3349. 2016. View Article : Google Scholar : PubMed/NCBI
2	Moretta L: Dissecting CD56^dim human NK cells. Blood. 116:3689–3691. 2010. View Article : Google Scholar : PubMed/NCBI
3	Kannan GS, Aquino-Lopez A and Lee DA: Natural killer cells in malignant hematology: A primer for the non-immunologist. Blood Rev. 31:1–10. 2017. View Article : Google Scholar : PubMed/NCBI
4	Farag SS, Fehniger TA, Ruggeri L, Velardi A and Caligiuri MA: Natural killer cell receptors: New biology and insights into the graft-versus-leukemia effect. Blood. 100:1935–1947. 2002. View Article : Google Scholar : PubMed/NCBI
5	Sun PD: Structure and function of natural-killer-cell receptors. Immunol Res. 27:539–548. 2003. View Article : Google Scholar : PubMed/NCBI
6	Willcox BE, Thomas LM and Bjorkman PJ: Crystal structure of HLA-A2 bound to LIR-1, a host and viral major histocompatibility complex receptor. Nat Immunol. 4:913–919. 2003. View Article : Google Scholar : PubMed/NCBI
7	Joyce MG, Tran P, Zhuravleva MA, Jaw J, Colonna M and Sun PD: Crystal structure of human natural cytotoxicity receptor NKp30 and identification of its ligand binding site. Proc Natl Acad Sci USA. 108:6223–6228. 2011. View Article : Google Scholar : PubMed/NCBI
8	Suck G, Linn YC and Tonn T: Natural killer cells for therapy of leukemia. Transfus Med Hemother. 43:89–95. 2016. View Article : Google Scholar : PubMed/NCBI
9	Parham P and Moffett A: Variable NK cell receptors and their MHC class I ligands in immunity, reproduction and human evolution. Nat Rev Immunol. 13:133–144. 2013. View Article : Google Scholar : PubMed/NCBI
10	Muntasel A, Ochoa MC, Cordeiro L, Berraondo P, López-Díaz de Cerio A, Cabo M, López-Botet M and Melero I: Targeting NK-cell checkpoints for cancer immunotherapy. Curr Opin Immunol. 45:73–81. 2017. View Article : Google Scholar : PubMed/NCBI
11	Lanier LL: Natural killer cell receptor signaling. Curr Opin Immunol. 15:308–314. 2003. View Article : Google Scholar : PubMed/NCBI
12	Sentman CL, Barber MA, Barber A and Zhang T: NK cell receptors as tools in cancer immunotherapy. Adv Cancer Res. 95:249–292. 2006. View Article : Google Scholar : PubMed/NCBI
13	Vivier E, Nune JA and Vély F: Natural killer cell signaling pathways. Science. 306:1517–1519. 2004. View Article : Google Scholar : PubMed/NCBI
14	Linnartz B, Wang Y and Neumann H: Microglial immunoreceptor tyrosine-based activation and inhibition motif signaling in neuroinflammation. Int J Alzheimers Dis. 2010:5874632010.PubMed/NCBI
15	Pugh JL, Nemat-Gorgani N, Norman PJ, Guethlein LA and Parham P: Human NK cells downregulate Zap70 and Syk in response to prolonged activation or DNA damage. J Immunol. 200:1146–1158. 2018. View Article : Google Scholar : PubMed/NCBI
16	Teresa Rios-Paredes: Use of NK cells in haematological cancer therapy. Faculty of Medicine University of Oslo. 2014.
17	Verneris MR and Miller JS: KIR B or not to be?…that is the question for ALL. Blood. 124:2623–2624. 2014. View Article : Google Scholar : PubMed/NCBI
18	Gaafar A, Sheereen A, Almohareb F, Eldali A, Chaudhri N, Mohamed SY, Hanbali A, Shaheen M, Alfraih F, El Fakih R, et al: Prognostic role of KIR genes and HLA-C after hematopoietic stem cell transplantation in a patient cohort with acute myeloid leukemia from a consanguineous community. Bone Marrow Transplant. 58:1170–1179. 2018. View Article : Google Scholar
19	Long EO, Barber DF, Burshtyn DN, Faure M, Peterson M, Rajagopalan S, Renard V, Sandusky M, Stebbins CC, Wagtmann N, et al: Inhibition of natural killer cell activation signals by killer cell immunoglobulin-like receptors (CD158). Immunol Rev. 181:223–233. 2001. View Article : Google Scholar : PubMed/NCBI
20	Ruggeri L, Capanni M, Urbani E, Perruccio K, Shlomchik WD, Tosti A, Posati S, Rogaia D, Frassoni F, Aversa F, et al: Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science. 295:2097–2100. 2002. View Article : Google Scholar : PubMed/NCBI
21	Rajalingam R: Human diversity of killer cell immunoglobulin-like receptors and disease. Korean J Hematol. 46:216–228. 2011. View Article : Google Scholar : PubMed/NCBI
22	Fang F, Xiao W and Tian Z: NK cell-based immunotherapy for cancer. Semin Immunol. 31:37–54. 2017. View Article : Google Scholar : PubMed/NCBI
23	Ljunggren HG and Kärre K: In search of the missing self-MHC molecules and NK cell recognition. Immunol Today. 11:237–244. 1990. View Article : Google Scholar : PubMed/NCBI
24	Bottino C, Dondero A, Bellora F, Moretta L, Locatelli F, Pistoia V, Moretta A and Castriconi R: Natural killer cells and neuroblastoma: tumor recognition, escape mechanisms, and possible novel immunotherapeutic approaches. Front Immunol. 5:562014. View Article : Google Scholar : PubMed/NCBI
25	Carotta S: Targeting NK cells for anticancer immunotherapy: Clinical and preclinical approaches. Front Immunol. 7:1522016. View Article : Google Scholar : PubMed/NCBI
26	Martinet L and Smyth MJ: Balancing natural killer cell activation through paired receptors. Nat Rev Immunol. 15:243–254. 2015. View Article : Google Scholar : PubMed/NCBI
27	Shimasaki N, Coustan-Smith E, Kamiya T and Campana D: Expanded and armed natural killer cells for cancer treatment. Cytotherapy. 18:1422–1434. 2016. View Article : Google Scholar : PubMed/NCBI
28	Zhu Y, Huang B and Shi J: Fas ligand and lytic granule differentially control cytotoxic dynamics of natural killer cell against cancer target. Oncotarget. 7:47163–47172. 2016.PubMed/NCBI
29	Childs RW and Carlsten M: Therapeutic approaches to enhance natural killer cell cytotoxicity against cancer: The force awakens. Nat Rev Drug Discov. 14:487–498. 2015. View Article : Google Scholar : PubMed/NCBI
30	Nückel H, Switala M, Sellmann L, Horn PA, Dürig J, Dührsen U, Küppers R, Grosse-Wilde H and Rebmann V: The prognostic significance of soluble NKG2D ligands in B-cell chronic lymphocytic leukemia. Leukemia. 24:1152–1159. 2010. View Article : Google Scholar : PubMed/NCBI
31	Burger JA and Gribben JG: The microenvironment in chronic lymphocytic leukemia (CLL) and other B cell malignancies: Insight into disease biology and new targeted therapies. Semin Cancer Biol. 24:71–81. 2014. View Article : Google Scholar : PubMed/NCBI
32	Osman AE, AlJuryyan A, Alharthi H and Almoshary M: Association between the killer cell immunoglobulin-like receptor a haplotype and childhood acute lymphoblastic leukemia. Hum Immunol. 78:510–514. 2017. View Article : Google Scholar : PubMed/NCBI
33	Boissel N, Rea D, Tieng V, Dulphy N, Brun M, Cayuela JM, Rousselot P, Tamouza R, Le Bouteiller P, Mahon FX, et al: BCR/ABL oncogene directly controls MHC class I chain-related molecule A expression in chronic myelogenous leukemia. J Immunol. 176:5108–5116. 2006. View Article : Google Scholar : PubMed/NCBI
34	Maru Y: Molecular biology of chronic myeloid leukemia. Cancer Sci. 103:1601–1610. 2012. View Article : Google Scholar : PubMed/NCBI
35	https://www.ncbi.nlm.nih.gov/books/NBK65916/
36	Danier AC, de Melo RP, Napimoga MH and Laguna-Abreu MT: The role of natural killer cells in chronic myeloid leukemia. Rev Bras Hematol Hemoter. 33:216–220. 2011. View Article : Google Scholar : PubMed/NCBI
37	Huang CH, Liao YJ, Fan TH, Chiou TJ, Lin YH and Twu YC: A Developed NK-92MI cell line with Siglec-7^neg phenotype exhibits high and sustainable cytotoxicity against leukemia cells. Int J Mol Sci. 19:E10732018. View Article : Google Scholar : PubMed/NCBI
38	O'Brien SG, Guilhot F, Larson RA, Gathmann I, Baccarani M, Cervantes F, Cornelissen JJ, Fischer T, Hochhaus A, Hughes T, et al: Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med. 348:994–1004. 2003. View Article : Google Scholar : PubMed/NCBI
39	Rossignol A, Levescot A, Jacomet F, Robin A, Basbous S, Giraud C, Roy L, Guilhot F, Turhan AG, Barra A, et al: Evidence for BCR-ABL-dependent dysfunctions of iNKT cells from chronic myeloid leukemia patients. Eur J Immunol. 42:1870–1875. 2012. View Article : Google Scholar : PubMed/NCBI
40	Heaney NB and Holyoake TL: Therapeutic targets in chronic myeloid leukaemia. Hematol Oncol. 25:66–75. 2007. View Article : Google Scholar : PubMed/NCBI
41	Pophali PA and Patnaik MM: The role of new tyrosine kinase inhibitors in chronic myeloid leukemia. Cancer J. 22:40–50. 2016. View Article : Google Scholar : PubMed/NCBI
42	Shapira T, Pereg D and Lishner M: How I treat acute and chronic leukemia in pregnancy. Blood Rev. 22:247–259. 2008. View Article : Google Scholar : PubMed/NCBI
43	Goldman JM: How I treat chronic myeloid leukemia in the imatinib era. Blood. 110:2828–2837. 2007. View Article : Google Scholar : PubMed/NCBI
44	Garderet L, Santacruz R, Barbu V, van den Akker J, Carbonne B and Gorin NC: Two successful pregnancies in chronic myeloid leukemia patient treated with imatinib. Haematologica. 92:e9–e10. 2007. View Article : Google Scholar : PubMed/NCBI
45	Roth MS and Foon KA: Alpha interferon in the treatment of hematologic malignancies. Am J Med. 81:871–882. 1986. View Article : Google Scholar : PubMed/NCBI
46	Giallongo C, La Cava P, Tibullo D, Parrinello N, Barbagallo I, Del Fabro V, Stagno F, Conticello C, Romano A, Chiarenza A, et al: Imatinib increases cytotoxicity of melphalan and their combination allows an efficient killing of chronic myeloid leukemia cells. Eur J Haematol. 86:216–225. 2011. View Article : Google Scholar : PubMed/NCBI
47	Millicovsky G, DeSesso JM, Kleinman LI and Clark KE: Effects of hydroxyurea on hemodynamics of pregnant rabbits: A maternally mediated mechanism of embryotoxicity. Am J Obstet Gynecol. 140:747–752. 1981. View Article : Google Scholar : PubMed/NCBI
48	Thauvin-Robinet C, Maingueneau C, Robert E, Elefant E, Guy H, Caillot D, Casasnovas RO, Douvier S and Nivelon-Chevallier A: Exposure to hydroxyurea during pregnancy: A case series. Leukemia. 15:1309–1311. 2001. View Article : Google Scholar : PubMed/NCBI
49	Yellu M, Pinkard S, Ghose A and Medlin S: CML in pregnancy: A case report using leukapheresis and literature review. Transfus Apher Sci. 53:289–292. 2015. View Article : Google Scholar : PubMed/NCBI
50	Ali R, Ozkalemkaş F, Ozkocaman V, Ozçelik T, Ozan U, Kimya Y and Tunali A: Successful pregnancy and delivery in a patient with chronic myelogenous leukemia (CML), and management of CML with leukapheresis during pregnancy: A case report and review of the literature. Jpn J Clin Oncol. 34:215–217. 2004. View Article : Google Scholar : PubMed/NCBI
51	Cayssials E and Guilhot F: Chronic myeloid leukemia: Immunobiology and novel immunotherapeutic approaches. BioDrugs. 31:143–149. 2017. View Article : Google Scholar : PubMed/NCBI
52	Mahoney KM, Rennert PD and Freeman GJ: Combination cancer immunotherapy and new immunomodulatory targets. Nat Rev Drug Discov. 14:561–584. 2015. View Article : Google Scholar : PubMed/NCBI
53	Mumprecht S, Schürch C, Schwaller J, Solenthaler M and Ochsenbein AF: Programmed death 1 signaling on chronic myeloid leukemia-specific T cells results in T-cell exhaustion and disease progression. Blood. 114:1528–1536. 2009. View Article : Google Scholar : PubMed/NCBI
54	Zhang B, Chu S, Agarwal P, Campbell VL, Hopcroft L, Jørgensen HG, Lin A, Gaal K, Holyoake TL and Bhatia R: Inhibition of interleukin-1 signaling enhances elimination of tyrosine kinase inhibitor-treated CML stem cells. Blood. 128:2671–2682. 2016. View Article : Google Scholar : PubMed/NCBI
55	Ågerstam H, Hansen N, von Palffy S, Sandén C, Reckzeh K, Karlsson C, Lilljebjörn H, Landberg N, Askmyr M, Högberg C, et al: IL1RAP antibodies block IL-1-induced expansion of candidate CML stem cells and mediate cell killing in xenograft models. Blood. 128:2683–2693. 2016. View Article : Google Scholar : PubMed/NCBI
56	Arranz L, Arriero MD and Villatoro A: Interleukin-1β as emerging therapeutic target in hematological malignancies and potentially in their complications. Blood Rev. 31:306–317. 2017. View Article : Google Scholar : PubMed/NCBI
57	Zhao K, Yuan S, Yin L, Xia J and Xu K: Potential efficacy of human IL-1RAP specific CAR-T cell in eliminating leukemic stem cells of chronic myeloid leukemia. J Leukemia. 5:2322017. View Article : Google Scholar
58	Stramucci L and Perrotti D: Twisting IL-1 signaling to kill CML stem cells. Blood. 128:2592–2593. 2016. View Article : Google Scholar : PubMed/NCBI
59	Tarafdar A, Hopcroft LE, Gallipoli P, Pellicano F, Cassels J, Hair A, Korfi K, Jørgensen HG, Vetrie D, Holyoake TL, et al: CML cells actively evade host immune surveillance through cytokine-mediated downregulation of MHCII expression. Blood. 129:199–208. 2017. View Article : Google Scholar : PubMed/NCBI
60	Levescot A, Flamant S, Basbous S, Jacomet F, Féraud O, Anne Bourgeois E, Bonnet ML, Giraud C, Roy L, Barra A, et al: BCR-ABL-induced deregulation of the IL-33/ST2 pathway in CD34⁺ progenitors from chronic myeloid leukemia patients. Cancer Res. 74:2669–2676. 2014. View Article : Google Scholar : PubMed/NCBI
61	Rocca S, Carrà G, Poggio P, Morotti A and Brancaccio M: Targeting few to help hundreds: JAK, MAPK and ROCK pathways as druggable targets in atypical chronic myeloid leukemia. Mol Cancer. 17:402018. View Article : Google Scholar : PubMed/NCBI
62	Pierson BA and Miller JS: The role of autologous natural killer cells in chronic myelogenous leukemia. Leuk Lymphoma. 27:387–399. 1997. View Article : Google Scholar : PubMed/NCBI
63	Verfaillie C, Kay N, Miller W and McGlave P: Diminished A-LAK cytotoxicity and proliferation accompany disease progression in chronic myelogenous leukemia. Blood. 76:401–408. 1990.PubMed/NCBI
64	Pawelec G, Schneider E, Ehninger G, Rehbein A and Schmidt H: Partial correction of defective generation of lymphokine-activated killer cells in patients with chronic myelogenous leukaemia after in vivo treatment with interferon-alpha (Wellferon). Cancer Immunol Immunother. 29:63–66. 1989. View Article : Google Scholar : PubMed/NCBI
65	Mustjoki S, Ekblom M, Arstila TP, Dybedal I, Epling-Burnette PK, Guilhot F, Hjorth-Hansen H, Höglund M, Kovanen P, Laurinolli T, et al: Clonal expansion of T/NK-cells during tyrosine kinase inhibitor dasatinib therapy. Leukemia. 23:1398–1405. 2009. View Article : Google Scholar : PubMed/NCBI
66	Kijima M, Gardiol N and Held W: Natural killer cell mediated missing-self recognition can protect mice from primary chronic myeloid leukemia in vivo. PLoS One. 6:e276392011. View Article : Google Scholar : PubMed/NCBI
67	Zhao XY, Chang YJ, Xu LP, Zhang XH, Liu KY, Li D and Huang XJ: HLA and KIR genotyping correlates with relapse after T-cell-replete haploidentical transplantation in chronic myeloid leukaemia patients. Br J Cancer. 111:1080–1088. 2014. View Article : Google Scholar : PubMed/NCBI
68	Necchi A, Lanza F, Rosti G, Martino M, Farè E, Pedrazzoli P, European Society for Blood, Marrow Transplantation and Solid Tumors Working Party; (EBMT-STWP) the Italian Germ Cell Cancer Group (IGG), : High-dose chemotherapy for germ cell tumors: Do we have a model? Expert Opin Biol Ther. 15:33–44. 2015. View Article : Google Scholar : PubMed/NCBI
69	Zahid U, Akbar F, Amaraneni A, Husnain M, Chan O, Riaz IB, McBride A, Iftikhar A and Anwer F: A review of autologous stem cell transplantation in lymphoma. Curr Hematol Malig Rep. 12:217–226. 2017. View Article : Google Scholar : PubMed/NCBI
70	Kim S, Poursine-Laurent J, Truscott SM, Lybarger L, Song YJ, Yang L, French AR, Sunwoo JB, Lemieux S, Hansen TH, et al: Licensing of natural killer cells by host major histocompatibility complex class I molecules. Nature. 436:709–713. 2005. View Article : Google Scholar : PubMed/NCBI
71	Sivori S, Carlomagno S, Falco M, Romeo E, Moretta L and Moretta A: Natural killer cells expressing the KIR2DS1-activating receptor efficiently kill T-cell blasts and dendritic cells: Implications in haploidentical HSCT. Blood. 117:4284–4292. 2011. View Article : Google Scholar : PubMed/NCBI
72	Gabriel IH, Sergeant R, Szydlo R, Apperley JF, DeLavallade H, Alsuliman A, Khoder A, Marin D, Kanfer E, Cooper N, et al: Interaction between KIR3DS1 and HLA-Bw4 predicts for progression-free survival after autologous stem cell transplantation in patients with multiple myeloma. Blood. 116:2033–2039. 2010. View Article : Google Scholar : PubMed/NCBI
73	Middleton D, Diler AS, Meenagh A, Sleator C and Gourraud PA: Killer immunoglobulin-like receptors (KIR2DL2 and/or KIR2DS2) in presence of their ligand (HLA-C1 group) protect against chronic myeloid leukaemia. Tissue Antigens. 73:553–560. 2009. View Article : Google Scholar : PubMed/NCBI
74	Marin D, Gabriel IH, Ahmad S, Foroni L, de Lavallade H, Clark R, O'Brien S, Sergeant R, Hedgley C, Milojkovic D, et al: KIR2DS1 genotype predicts for complete cytogenetic response and survival in newly diagnosed chronic myeloid leukemia patients treated with imatinib. Leukemia. 26:296–302. 2012. View Article : Google Scholar : PubMed/NCBI
75	Kreutzman A, Jaatinen T, Greco D, Vakkila E, Richter J, Ekblom M, Hjorth-Hansen H, Stenke L, Melo T, Paquette R, et al: Killer-cell immunoglobulin-like receptor gene profile predicts good molecular response to dasatinib therapy in chronic myeloid leukemia. Exp Hematol. 40:906–913. 2012. View Article : Google Scholar : PubMed/NCBI
76	La Nasa G, Caocci G, Littera R, Atzeni S, Vacca A, Mulas O, Langiu M, Greco M, Orrù S, Orrù N, et al: Homozygosity for killer immunoglobin-like receptor haplotype A predicts complete molecular response to treatment with tyrosine kinase inhibitors in chronic myeloid leukemia patients. Exp Hematol. 41:424–431. 2013. View Article : Google Scholar : PubMed/NCBI
77	Zhao XY, Chang YJ and Huang XJ: Differential expression levels of killer immunoglobin-like receptor genotype in patients with hematological malignancies between high-risk and standard-risk groups. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 16:746–749. 2008.(In Chinese). PubMed/NCBI